BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

16 related articles for article (PubMed ID: 38578213)

  • 1. The prognostic effect of immunoscore in patients with clear cell renal cell carcinoma: preliminary results.
    Selvi I; Demirci U; Bozdogan N; Basar H
    Int Urol Nephrol; 2020 Jan; 52(1):21-34. PubMed ID: 31541404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study.
    Alwers E; Kather JN; Kloor M; Brobeil A; Tagscherer KE; Roth W; Echle A; Amitay EL; Chang-Claude J; Brenner H; Hoffmeister M
    J Pathol Clin Res; 2023 Mar; 9(2):129-136. PubMed ID: 36424650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abundant CD8+ tumor infiltrating lymphocytes and beta-2-microglobulin are associated with better outcome and response to interleukin-2 therapy in advanced stage clear cell renal cell carcinoma.
    Davis D; Tretiakova MS; Kizzar C; Woltjer R; Krajbich V; Tykodi SS; Lanciault C; Andeen NK
    Ann Diagn Pathol; 2020 Aug; 47():151537. PubMed ID: 32454441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases.
    Wang Y; Lin HC; Huang MY; Shao Q; Wang ZQ; Wang FH; Yuan YF; Li BK; Wang DS; Ding PR; Chen G; Wu XJ; Lu ZH; Li LR; Pan ZZ; Sun P; Yan SM; Wan DS; Xu RH; Li YH
    Cancer Immunol Immunother; 2018 Mar; 67(3):435-444. PubMed ID: 29204700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer.
    Kwak Y; Koh J; Kim DW; Kang SB; Kim WH; Lee HS
    Oncotarget; 2016 Dec; 7(49):81778-81790. PubMed ID: 27835889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD3+ and CD8+ T cell-based immune cell score as a prognostic factor in clear-cell renal cell carcinoma.
    Åkerla J; Helminen O; Väyrynen JP; Parkkinen A; Järvenpää H; Böhm J; Ahtiainen M; Seikkula H
    Acta Oncol; 2024 Mar; 63():105-110. PubMed ID: 38578213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.